InnAVasc Medical, Inc. is a medical device company founded by Duke University surgeons and scientists, specializing in the design and development of advanced vascular access products for hemodialysis. The company's flagship product is an arteriovenous graft (AVG) modification that features two multilayer cannulation chambers. These chambers are designed with low bleed technology and are resistant to posterior and sidewall needle penetration, significantly reducing the risk of adverse events and device failures associated with repeated vascular access.

InnAVasc primarily serves patients with end-stage renal disease who require hemodialysis, a market that is both critical and growing. The company's business model focuses on the development and commercialization of innovative medical devices that address common complications in vascular access for dialysis patients. Revenue is generated through the sale of these specialized grafts to healthcare providers and institutions.

By addressing the common issues of graft degradation, pseudoaneurysm formation, and the associated complications such as thrombosis and infection, InnAVasc aims to improve patient outcomes and reduce healthcare costs. The company's technology is particularly significant in reducing the need for surgical interventions and minimizing patient pain and disability.

Keywords: arteriovenous graft, hemodialysis, vascular access, low bleed technology, Duke University, medical device, end-stage renal disease, pseudoaneurysm, thrombosis, healthcare innovation.